🔓 Unlock the full profile of Omid Farokhzad (Seer), including verified contact details, financial insights, and professional associations.
See Omid Farokhzad Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: omi*****@see******.com
Mobile: 80285*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Omid Farokhzad is the Chair, CEO, and Founder of Seer, a biotechnology company established in 2017, specializing in next-generation proteomics.
- Seer is publicly traded on NASDAQ under the symbol SEER, with a current market capitalization of approximately $113 million.
- Under Farokhzad's leadership, Seer has developed innovative platforms that utilize proteomic technology for drug discovery and diagnostics, making significant strides in precision medicine.
- Prior to founding Seer, Farokhzad was involved in various leadership roles, including serving as a Professor of Anesthesiology at Harvard Medical School from 2004 to present.
- Farokhzad has also held positions in several other biotech companies, including being the Chair and Founder of PrognomiQ Inc, which focuses on utilizing proteomics for early disease detection.
- Farokhzad played a crucial role in establishing and directing the Center for Nanomedicine at Brigham and Women's Hospital from 2016 to 2020, which focuses on the application of nanotechnology in medicine.
- Throughout the career, Farokhzad has been an advocate for translating scientific advancements into clinical applications, contributing numerous publications and patents in the field.
- Challenges faced while building Seer include navigating the complexities of biotech startup funding, regulatory hurdles, and the competitive landscape of biotechnology.
- Despite these challenges, Farokhzad's vision and leadership have positioned Seer as a key player in the biotech industry, driving advancements in healthcare technology.